<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511417827</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511417827</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Sonder</surname><given-names>JM</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511417827">1</xref>
<xref ref-type="aff" rid="aff2-1352458511417827">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bosma</surname><given-names>LVAE</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511417827">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>van der Linden</surname><given-names>FAH</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511417827">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Knol</surname><given-names>DL</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511417827">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511417827">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Uitdehaag</surname><given-names>BMJ</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511417827">1</xref>
<xref ref-type="aff" rid="aff2-1352458511417827">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511417827"><label>1</label>Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.</aff>
<aff id="aff2-1352458511417827"><label>2</label>Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands.</aff>
<author-notes>
<corresp id="corresp1-1352458511417827">JM Sonder, VU University Medical Center, Department of Neurology, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands Email: <email>judith.sonder@vumc.nl</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>2</issue>
<fpage>196</fpage>
<lpage>201</lpage>
<history>
<date date-type="received">
<day>3</day>
<month>12</month>
<year>2010</year>
</date>
<date date-type="rev-recd">
<day>17</day>
<month>5</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>6</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Background:</bold> Patient-reported outcome (PRO) scales are often used in multiple sclerosis (MS) research. Full understanding of items can be influenced by disease worsening, mood disturbances and cognitive problems of the MS patient. Earlier research with the Multiple Sclerosis Impact Scale (MSIS-29) showed that proxy respondents (i.e. partners of patients) can provide useful information.</p>
<p><bold>Objective:</bold> To determine agreement between patients and proxy respondents on different MS PRO scales.</p>
<p><bold>Methods:</bold> 139 Patients and partners completed the MSIS-29 (Physical and Psychological scale), Multiple Sclerosis Walking Scale (MSWS-12), Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ) and Guy’s Neurological Disability Scale (GNDS). We calculated the mean difference and intra-class correlation coefficients (ICC) on scale level and weighted kappas (κ<sub>w</sub>) on item level.</p>
<p><bold>Results:</bold> On all scales, except MSNQ, the partner score was higher. ICCs were good for MSWS, GNDS and MSIS Physical, and moderate for MSNQ and MSIS Psychological. κ<sub>w</sub> was excellent for MSWS items, fair to good for GNDS, MSIS Physical and MSIS Psychological items, and poor for MSNQ items.</p>
<p><bold>Conclusion:</bold> Partners of patients with MS can be a useful source of information for several PRO scales, especially when the focus is on physical functioning. For psychological functioning this seems to be less reliable.</p>
</abstract>
<kwd-group>
<kwd>agreement</kwd>
<kwd>disability</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>outcome assessment</kwd>
<kwd>patient-reported outcomes</kwd>
<kwd>proxy respondents</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458511417827" sec-type="intro">
<title>Introduction</title>
<p>Multiple Sclerosis (MS) is a chronic disease with a variable pattern. Many instruments and scales have been developed to look at effects of MS on physical state, psychological state, cognition, mood and quality of life. The measurement instruments can be ratings of clinicians or patient-reported outcome (PRO) scales. For some of these latter instruments there are also informant versions available, developed to be completed by healthcare providers or proxy respondents.</p>
<p>Researchers in MS often have to deal with loss of information and loss to follow-up as a result of disease burden. The time points of this methodological problem are not random, but are often critical points in the disease of the patient in which important information about their health status should be collected. Moreover, a full understanding of self-report forms and the ability of the patient to respond adequately can be influenced by disease worsening, fatigue, mood disturbances and cognitive problems due to MS.<sup><xref ref-type="bibr" rid="bibr1-1352458511417827">1</xref></sup> Therefore including proxy respondents (i.e. partners of patients) to evaluate the disease state of the patient might be useful to continue reliable follow-up research.<sup><xref ref-type="bibr" rid="bibr2-1352458511417827">2</xref></sup></p>
<p>We described in previous studies with relative small groups of patients<sup><xref ref-type="bibr" rid="bibr3-1352458511417827">3</xref>–<xref ref-type="bibr" rid="bibr7-1352458511417827">7</xref></sup> that there is agreement on the Multiple Sclerosis Impact Scale (MSIS-29)<sup><xref ref-type="bibr" rid="bibr8-1352458511417827">8</xref></sup> between patients and proxy respondents on group level. The objective of this study was to extend this research to other PRO scales concerning MS. To investigate this objective we used a range of MS scales, from what we hypothesized was more easy to observe (walking ability, physical functioning), intermediately difficult to observe (overall disability), and difficult to observe (psychological functioning). We hypothesized that agreement was better on well-observable scales and more differences would be seen on psychological scales. We were also interested in the size and direction of possible differences and the influence of the level of disability.</p>
</sec>
<sec id="section2-1352458511417827" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1352458511417827">
<title>Patients and test procedures</title>
<p>The subjects (aged 18 years or older) in this study were patients with MS and their partners, functioning as proxy respondents. When the partner could not come to the hospital, the PRO scales were completed at home and the partner was interviewed by phone. The medical ethical committee of the VU University Medical Center approved the study protocol.</p>
</sec>
<sec id="section4-1352458511417827">
<title>Tests</title>
<p>The MSIS-29 measures disease impact of MS on daily life and can be divided into two subscales: a physical scale (MSIS Physical) which consists of 20 items and a psychological scale (MSIS Psychological) with nine items. The Multiple Sclerosis Walking Scale (MSWS-12)<sup><xref ref-type="bibr" rid="bibr9-1352458511417827">9</xref></sup> is a patient-based measure of walking ability in MS with a 12-item scale, restricted to patients who can walk. Guy’s Neurological Disability Scale (GNDS)<sup><xref ref-type="bibr" rid="bibr10-1352458511417827">10</xref></sup> is an interview-based questionnaire measuring disability in MS. The items include cognition, mood, vision, speech, swallowing, upper limb function, lower limb function, bladder function, bowel function, sexual function, fatigue and ‘others’. The Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ)<sup><xref ref-type="bibr" rid="bibr11-1352458511417827">11</xref></sup> is a brief self-administered questionnaire with 15 items that reflects neuropsychological competence in patients with MS during activities of daily living. The Extended Disability Status Scale (EDSS)<sup><xref ref-type="bibr" rid="bibr12-1352458511417827">12</xref></sup> assesses neurological impairment and disability. EDSS score varies between 0 and 10; a higher score indicates more severe disability.</p>
</sec>
<sec id="section5-1352458511417827">
<title>Data analyses</title>
<p>All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 14.0 (SPSS, Inc., Chicago, IL., USA) and Stata 11.1 (StataCorp, College Station, TX, USA, 2009).</p>
<sec id="section6-1352458511417827">
<title>Agreement at scale level</title>
<p>As an indicator of agreement at scale level, the mean difference (<italic>d</italic>) between patient and proxy was calculated for all scale scores. A positive mean indicated a higher scale score for the patient, a negative mean was a higher score reported by the proxy respondent. To be able to compare the different scales, all scores were converted to a 0–100 scale using the formula:<sup><xref ref-type="bibr" rid="bibr13-1352458511417827">13</xref></sup></p>
<p>
<disp-formula id="disp-formula1-1352458511417827">
<mml:math display="block" id="math1-1352458511417827">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mn>100</mml:mn>
<mml:mo>×</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>observer score</mml:mtext>
<mml:mo>−</mml:mo>
<mml:mtext>minimum score</mml:mtext>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mtext>maximum score</mml:mtext>
<mml:mo>−</mml:mo>
<mml:mtext>minimum score</mml:mtext>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1352458511417827" xlink:href="10.1177_1352458511417827-eq1.tif"/>
</disp-formula>
</p>
<p>For all scales, paired sample <italic>t</italic>-tests were used to see whether the patient and proxy scores were significantly different. With analyses of variance (ANOVA) we tested whether there were differences between the proxy respondents participating in the hospital and at home, and also between more (EDSS ≥ 6) and less (EDSS &lt; 6) disabled patients.</p>
<p>In Bland and Altman plots<sup><xref ref-type="bibr" rid="bibr14-1352458511417827">14</xref></sup> the differences between patient–proxy paired scale scores were plotted against the mean score of each pair. Furthermore, limits of agreement (LoA) were calculated using the mean difference per scale (<italic>d</italic>) and the standard deviation of the difference (SD<sub>difference</sub>):</p>
<p>
<disp-formula id="disp-formula2-1352458511417827">
<mml:math display="block" id="math2-1352458511417827">
<mml:mi>d</mml:mi>
<mml:mo>±</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>96</mml:mn>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mtext>SD</mml:mtext>
<mml:mrow>
<mml:mtext>difference</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>.</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula2-1352458511417827" xlink:href="10.1177_1352458511417827-eq2.tif"/>
</disp-formula>
</p>
<p>Internal consistency of each scale was assessed using Cronbach’s alpha. Pearson correlations were computed as a measure of the statistical dependence between the different patient scales and separate for the proxy scales. Inter-observer reliability between ratings of patients and proxy respondents was calculated using the intra-class correlation coefficients (ICC) two-way mixed model for absolute agreement.<sup><xref ref-type="bibr" rid="bibr15-1352458511417827">15</xref></sup> An ICC higher than 0.70 was considered to be acceptable.<sup><xref ref-type="bibr" rid="bibr16-1352458511417827">16</xref></sup></p>
</sec>
<sec id="section7-1352458511417827">
<title>Agreement at item level</title>
<p>Cohen’s weighted kappa<sup><xref ref-type="bibr" rid="bibr17-1352458511417827">17</xref></sup> was used to evaluate inter-rater agreement on item level. For interpretation, the mean weighted kappas of the five scales were classified according to Fleiss:<sup><xref ref-type="bibr" rid="bibr18-1352458511417827">18</xref></sup> excellent (κ<sub>w</sub> &gt; 0.75), fair to good (0.40 ≤ κ<sub>w</sub> ≤ 0.75) and poor (κ<sub>w</sub> &lt; 0.40).</p>
</sec>
</sec>
</sec>
<sec id="section8-1352458511417827" sec-type="results">
<title>Results</title>
<sec id="section9-1352458511417827">
<title>Study sample</title>
<p>The characteristics of the study sample are shown in <xref ref-type="table" rid="table1-1352458511417827">Table 1</xref>. Of the proxy respondents, 66% attended the patient in the hospital visit and 34% participated at home.</p>
<table-wrap id="table1-1352458511417827" position="float">
<label>Table 1.</label>
<caption>
<p>Characteristics of the study sample</p>
</caption>
<graphic alternate-form-of="table1-1352458511417827" xlink:href="10.1177_1352458511417827-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Patient</th>
<th align="left">Proxy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male<sup><xref ref-type="table-fn" rid="table-fn1-1352458511417827">a</xref></sup></td>
<td>53 (38.1)</td>
<td>84 (60.4)</td>
</tr>
<tr>
<td>Female<sup><xref ref-type="table-fn" rid="table-fn1-1352458511417827">a</xref></sup></td>
<td>86 (61.9)</td>
<td>55 (39.6)</td>
</tr>
<tr>
<td>Age in years<sup><xref ref-type="table-fn" rid="table-fn2-1352458511417827">b</xref></sup></td>
<td>53.0 (43.0–62.0)</td>
<td>54.0 (44.0–62.0)</td>
</tr>
<tr>
<td>Relapsing–Remitting (RR)<sup><xref ref-type="table-fn" rid="table-fn1-1352458511417827">a</xref></sup></td>
<td>58 (41.7)</td>
<td>na</td>
</tr>
<tr>
<td>Secondary Progressive (SP)<sup><xref ref-type="table-fn" rid="table-fn1-1352458511417827">a</xref></sup></td>
<td>41 (29.5)</td>
<td>na</td>
</tr>
<tr>
<td>Primary Progressive (PP)<sup><xref ref-type="table-fn" rid="table-fn1-1352458511417827">a</xref></sup></td>
<td>36 (25.9)</td>
<td>na</td>
</tr>
<tr>
<td>Clinically Isolated Syndrome (CIS)<sup><xref ref-type="table-fn" rid="table-fn1-1352458511417827">a</xref></sup></td>
<td>4 (2.9)</td>
<td>na</td>
</tr>
<tr>
<td>Disease duration in years<sup><xref ref-type="table-fn" rid="table-fn2-1352458511417827">b</xref></sup></td>
<td>15.0 (9.0–22.0)</td>
<td>na</td>
</tr>
<tr>
<td>EDSS<sup><xref ref-type="table-fn" rid="table-fn2-1352458511417827">b</xref></sup></td>
<td>4.5 (2.5–6.5)</td>
<td>na</td>
</tr>
<tr>
<td>EDSS &lt;6<sup><xref ref-type="table-fn" rid="table-fn1-1352458511417827">a</xref></sup></td>
<td>84.0 (60.0)</td>
<td>na</td>
</tr>
<tr>
<td>EDSS ≥6<sup><xref ref-type="table-fn" rid="table-fn1-1352458511417827">a</xref></sup></td>
<td>54.0 (39.0)</td>
<td>na</td>
</tr>
<tr>
<td>MSIS-29 Physical (20 items)<sup><xref ref-type="table-fn" rid="table-fn2-1352458511417827">b</xref></sup></td>
<td>33.8 (12.5–53.8)</td>
<td>36.3 (16.3–54.1)<sup><xref ref-type="table-fn" rid="table-fn3-1352458511417827">c</xref></sup></td>
</tr>
<tr>
<td>MSWS (12 items)<sup><xref ref-type="table-fn" rid="table-fn2-1352458511417827">b</xref></sup></td>
<td>39.6 (12.5–69.8)</td>
<td>44.8 (10.4–74.5)<sup><xref ref-type="table-fn" rid="table-fn3-1352458511417827">c</xref></sup></td>
</tr>
<tr>
<td>GNDS (12 items)<sup><xref ref-type="table-fn" rid="table-fn2-1352458511417827">b</xref></sup></td>
<td>21.7 (12.9–33.3)</td>
<td>25.0 (12.9–33.3)<sup><xref ref-type="table-fn" rid="table-fn3-1352458511417827">c</xref></sup></td>
</tr>
<tr>
<td>MSNQ (15 items)<sup><xref ref-type="table-fn" rid="table-fn2-1352458511417827">b</xref></sup></td>
<td>28.3 (20.0–40.0)</td>
<td>23.3 (15.0–38.3)<sup><xref ref-type="table-fn" rid="table-fn3-1352458511417827">c</xref></sup></td>
</tr>
<tr>
<td>MSIS-29 Psychological (9 items)<sup><xref ref-type="table-fn" rid="table-fn2-1352458511417827">b</xref></sup></td>
<td>19.4 (8.3–33.3)</td>
<td>25.0 (13.2–44.4)<sup><xref ref-type="table-fn" rid="table-fn3-1352458511417827">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511417827"><label>a</label>
<p>N (%).</p>
</fn>
<fn id="table-fn2-1352458511417827"><label>b</label>
<p>Median (IQR).</p>
</fn>
<fn id="table-fn3-1352458511417827"><label>c</label>
<p>Proxy report of patient data.</p>
</fn>
<fn id="table-fn4-1352458511417827">
<p>na= not applicable.</p>
</fn>
<fn id="table-fn5-1352458511417827">
<p>EDSS, Expanded Disability Status Scale; MSIS, Multiple Sclerosis Impact Scale; MSWS, Multiple Sclerosis Walking Scale; GNDS, Guy’s Neurological Disability Scale; MSNQ, Multiple Sclerosis Neuropsychological Screening Questionnaire.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-1352458511417827">
<title>Data analyses</title>
<sec id="section11-1352458511417827">
<title>Agreement at scale level</title>
<p>The results of the agreement between patient and proxy respondent at scale level are shown in <xref ref-type="table" rid="table2-1352458511417827">Table 2</xref>. A significant difference between patient and proxy score (<italic>p</italic> &lt; 0.05) was found for the MSIS-29 Psychological scale and the GNDS. There were no significant differences in agreement between couples in which the proxy completed the questionnaires at home compared with those who came to the hospital, and also no differences were found between groups with more or less-disabled patients.</p>
<table-wrap id="table2-1352458511417827" position="float">
<label>Table 2.</label>
<caption>
<p>Agreement between patient and proxy respondent at scale score level</p>
</caption>
<graphic alternate-form-of="table2-1352458511417827" xlink:href="10.1177_1352458511417827-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th rowspan="2"/>
<th align="left" rowspan="2" valign="bottom">N (pairs)</th>
<th align="left" colspan="4">Difference in scale score (patient – proxy)</th>
</tr>
<tr>
<th align="left"><italic>d</italic></th>
<th align="left">SD<sub>difference</sub></th>
<th align="left">Range</th>
<th align="left"><italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSIS Physical</td>
<td>138</td>
<td>−1.1</td>
<td>14.7</td>
<td>−67.5;38.8</td>
<td>0.37</td>
</tr>
<tr>
<td>MSWS</td>
<td>115<sup><xref ref-type="table-fn" rid="table-fn6-1352458511417827">†</xref></sup></td>
<td>−1.3</td>
<td>13.9</td>
<td>−39.6;31.3</td>
<td>0.32</td>
</tr>
<tr>
<td>GNDS</td>
<td>137</td>
<td>−1.6</td>
<td>7.6</td>
<td>−35.0;21.7</td>
<td>0.02</td>
</tr>
<tr>
<td>MSNQ</td>
<td>134</td>
<td>1.8</td>
<td>15.9</td>
<td>−58.3;45.0</td>
<td>0.19</td>
</tr>
<tr>
<td>MSIS Psychological</td>
<td>138</td>
<td>−6.6</td>
<td>18.8</td>
<td>−66.7;44.4</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1352458511417827"><label>†</label>
<p>Scale is restricted to patients who can walk.</p>
</fn>
<fn id="table-fn7-1352458511417827">
<p>MSIS, Multiple Sclerosis Impact Scale; MSWS, Multiple Sclerosis Walking Scale; GNDS, Guy’s Neurological Disability Scale; MSNQ, Multiple Sclerosis Neuropsychological Screening Questionnaire.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="fig" rid="fig1-1352458511417827">Figures 1</xref> and <xref ref-type="fig" rid="fig2-1352458511417827">2</xref> show examples of patterns in Bland and Altman plots. On the MSIS Physical scale the lower points of agreement were found around the median, indicating that agreement was better for higher and lower scores. The mean difference was found to be small. The MSWS (<xref ref-type="fig" rid="fig1-1352458511417827">Figure 1</xref>) was scored on the total scale range; the plot showed that there was better agreement on the beginning (no problems with walking) and at the end of the scale (walking is extremely difficult). The GNDS was scored in small LoA. The differences between patient and proxy scores on the MSNQ (<xref ref-type="fig" rid="fig2-1352458511417827">Figure 2</xref>) were variable and there were fewer scores in the higher part of the scale. The MSIS Psychological scale showed good agreement on low scale scores, but agreement decreased with an increasing scale score. Proxy respondents scored higher than patients, with a large mean difference (−6.6) compared with the other scales.</p>
<fig id="fig1-1352458511417827" position="float">
<label>Figure 1.</label>
<caption>
<p>Bland and Altman Multiple Sclerosis Walking Scale (MSWS).</p>
</caption>
<graphic xlink:href="10.1177_1352458511417827-fig1.tif"/>
</fig>
<fig id="fig2-1352458511417827" position="float">
<label>Figure 2.</label>
<caption>
<p>Bland and Altman Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ).</p>
</caption>
<graphic xlink:href="10.1177_1352458511417827-fig2.tif"/>
</fig>
<p><xref ref-type="table" rid="table3-1352458511417827">Table 3</xref> presents the correlations of the patient and proxy scales. All correlations were positive and showed that there were strong similarities between the observed correlations for patient and informant scales. The tables also contain Cronbach’s alpha; all alphas were ≥0.80.</p>
<table-wrap id="table3-1352458511417827" position="float">
<label>Table 3.</label>
<caption>
<p>Pearson correlations of patient and proxy scales and Cronbach’s alpha on the diagonal</p>
</caption>
<graphic alternate-form-of="table3-1352458511417827" xlink:href="10.1177_1352458511417827-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">MSIS Physical</th>
<th align="left">MSWS</th>
<th align="left">GNDS</th>
<th align="left">MSNQ</th>
<th align="left">MSIS Psychological</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">Patient scales</td>
</tr>
<tr>
<td> MSIS Physical</td>
<td><bold>0.97</bold></td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> MSWS</td>
<td>0.85</td>
<td><bold>0.97</bold></td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> GNDS</td>
<td>0.81</td>
<td>0.73</td>
<td><bold>0.82</bold></td>
<td/>
<td/>
</tr>
<tr>
<td> MSNQ</td>
<td>0.45</td>
<td>0.38</td>
<td>0.49</td>
<td><bold>0.92</bold></td>
<td/>
</tr>
<tr>
<td> MSIS Psychological</td>
<td>0.73</td>
<td>0.52</td>
<td>0.66</td>
<td>0.66</td>
<td><bold>0.88</bold></td>
</tr>
<tr>
<td colspan="6">Proxy scales</td>
</tr>
<tr>
<td> MSIS Physical</td>
<td><bold>0.96</bold></td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> MSWS</td>
<td>0.89</td>
<td><bold>0.98</bold></td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> GNDS</td>
<td>0.81</td>
<td>0.75</td>
<td><bold>0.80</bold></td>
<td/>
<td/>
</tr>
<tr>
<td> MSNQ</td>
<td>0.52</td>
<td>0.40</td>
<td>0.65</td>
<td><bold>0.94</bold></td>
<td/>
</tr>
<tr>
<td> MSIS Psychological</td>
<td>0.66</td>
<td>0.48</td>
<td>0.64</td>
<td>0.61</td>
<td><bold>0.90</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-1352458511417827">
<p>MSIS, Multiple Sclerosis Impact Scale; MSWS, Multiple Sclerosis Walking Scale; GNDS, Guy’s Neurological Disability Scale; MSNQ, Multiple Sclerosis Neuropsychological Screening Questionnaire.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The ICCs are shown in <xref ref-type="table" rid="table4-1352458511417827">Table 4</xref> with their 95% confidence interval (CI). The coefficients were good for MSWS, MSIS Physical and GNDS. For MSIS Psychological and MSNQ the correlations between patient and partner ratings were small.</p>
<table-wrap id="table4-1352458511417827" position="float">
<label>Table 4.</label>
<caption>
<p>Intraclass correlation coefficients (ICC) and mean weighted kappa (κ<sub>w</sub>)</p>
</caption>
<graphic alternate-form-of="table4-1352458511417827" xlink:href="10.1177_1352458511417827-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left"><italic>N</italic> (pairs)</th>
<th align="left">ICC</th>
<th align="left">95% CI</th>
<th align="left">κ<sub>w</sub> mean</th>
<th align="left">range</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSIS-29 Physical (20)</td>
<td>138</td>
<td>0.82</td>
<td>0.76–0.87</td>
<td>0.61</td>
<td>0.47–0.77</td>
</tr>
<tr>
<td>MSWS (12)</td>
<td>115</td>
<td>0.91</td>
<td>0.87–0.94</td>
<td>0.78</td>
<td>0.69–0.89</td>
</tr>
<tr>
<td>GNDS (12)</td>
<td>137</td>
<td>0.86</td>
<td>0.80–0.90</td>
<td>0.64</td>
<td>0.39–0.92</td>
</tr>
<tr>
<td>MSNQ (15)</td>
<td>134</td>
<td>0.59</td>
<td>0.47–0.69</td>
<td>0.39</td>
<td>0.28–0.50</td>
</tr>
<tr>
<td>MSIS-29 Psychological (9)</td>
<td>138</td>
<td>0.55</td>
<td>0.40–0.67</td>
<td>0.44</td>
<td>0.18–0.68</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-1352458511417827">
<p>MSIS, Multiple Sclerosis Impact Scale; MSWS, Multiple Sclerosis Walking Scale; GNDS, Guy’s Neurological Disability Scale; MSNQ, Multiple Sclerosis Neuropsychological Screening Questionnaire.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-1352458511417827">
<title>Agreement at item level</title>
<p>Mean Cohen’s weighted kappa varied per scale (<xref ref-type="table" rid="table4-1352458511417827">Table 4</xref>). Excellent agreement was found for MSWS items; the lowest kappa for an item on this scale was 0.69. Fair to good agreement was found for GNDS, MSIS Physical and MSIS Psychological. The MSNQ showed poor agreement: no kappa higher then 0.50 was found, and 8 of 15 items showed a kappa smaller than 0.40.</p>
</sec>
</sec>
</sec>
<sec id="section13-1352458511417827" sec-type="discussion">
<title>Discussion</title>
<p>The aim of this study was to explore the agreement between patients and proxy respondents on different PRO scales for MS. As we hypothesized, agreement was seen on scales measuring physical functioning and walking ability of the MS patient, with high ICC values and good to excellent weighted kappas. Our data support previous findings that proxy respondents can rate the disease status of patients in an accurate way,<sup><xref ref-type="bibr" rid="bibr3-1352458511417827">3</xref></sup> when the focus is on specific and observable disease aspects or (physical) limitations.<sup><xref ref-type="bibr" rid="bibr2-1352458511417827">2</xref></sup></p>
<p>For psychological functioning (MSNQ and MSIS Psychological) and overall disability (GNDS) the differences between patients and proxy respondents were large and dependent of scale score. Factors influencing the differences on psychological scales should be further investigated using longitudinal data of PRO scales, cognitive testing and evaluation of mood and anxiety.</p>
<p>We found no differences between groups with more or less-disabled patients, indicating that proxy respondents can provide useful information in both groups. However, it is important to stress that results of this study may not be applicable to individual patient–proxy couples. Further research to identify individual variables that can predict agreement or disagreement more accurate is ongoing.</p>
<p>Concluding, we confirmed that partners of patients with MS can be a useful source of information for several PRO scales, especially when the focus is on physical functioning. Further research on factors that can influence (dis)agreement in comparison with additional variables and follow-up data is required.</p>
</sec>
</body>
<back>
<ack>
<p>We would like to thank the MS patients and partners who participated in this study.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>The MS Center VUmc is partially funded by a program grant of the Dutch MS Research Foundation.</p>
</fn>
<fn fn-type="conflict">
<p>There are no disclosures.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511417827">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tripoliti</surname><given-names>E</given-names></name>
<name><surname>Campbell</surname><given-names>C</given-names></name>
<name><surname>Pring</surname><given-names>T</given-names></name>
<name><surname>Taylor-Goh</surname><given-names>S</given-names></name>
</person-group>. <article-title>Quality of life in multiple sclerosis: should clinicians trust proxy ratings?</article-title> <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>1190</fpage>–<lpage>1194</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511417827">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sprangers</surname><given-names>MA</given-names></name>
<name><surname>Aaronson</surname><given-names>NK</given-names></name>
</person-group>. <article-title>The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review</article-title>. <source>J Clin Epidemiol</source> <year>1992</year>; <volume>45</volume>: <fpage>743</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511417827">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van der Linden</surname><given-names>FA</given-names></name>
<name><surname>Kragt</surname><given-names>JJ</given-names></name>
<name><surname>Klein</surname><given-names>M</given-names></name>
<name><surname>van der Ploeg</surname><given-names>HM</given-names></name>
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Uitdehaag</surname><given-names>BMJ</given-names></name>
</person-group>. <article-title>Psychometric evaluation of the Multiple Sclerosis Impact Scale (MSIS-29) for proxy use</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2005</year>; <volume>76</volume>: <fpage>1677</fpage>–<lpage>1681</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511417827">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van der Linden</surname><given-names>FA</given-names></name>
<name><surname>Kragt</surname><given-names>JJ</given-names></name>
<name><surname>Hobart</surname><given-names>JC</given-names></name>
<name><surname>Klein</surname><given-names>M</given-names></name>
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
<name><surname>van der Ploeg</surname><given-names>HM</given-names></name>
<etal/>
</person-group>. <article-title>Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2006</year>; <volume>77</volume>: <fpage>1157</fpage>–<lpage>1162</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511417827">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van der Linden</surname><given-names>FA</given-names></name>
<name><surname>D’hooghe</surname><given-names>MB</given-names></name>
<name><surname>Nagels</surname><given-names>G</given-names></name>
<name><surname>van Nunen</surname><given-names>A</given-names></name>
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Uitdehaag</surname><given-names>BMJ</given-names></name>
</person-group>. <article-title>Proxy ratings from multiple sources: disagreement on the impact of multiple sclerosis on daily life</article-title>. <source>Eur J Neurol</source> <year>2008</year>; <volume>15</volume>: <fpage>933</fpage>–<lpage>939</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511417827">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van der Linden</surname><given-names>FA</given-names></name>
<name><surname>Kragt</surname><given-names>JJ</given-names></name>
<name><surname>van Bon</surname><given-names>M</given-names></name>
<name><surname>Klein</surname><given-names>M</given-names></name>
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
<name><surname>van der Ploeg</surname><given-names>HM</given-names></name>
<etal/>
</person-group>. <article-title>Longitudinal proxy measurements in multiple sclerosis: patient–proxy agreement on the impact of MS on daily life over a period of two years</article-title>. <source>BMC Neurol</source> <year>2008</year>; <volume>8</volume>: <fpage>2</fpage>.</citation>
</ref>
<ref id="bibr7-1352458511417827">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van der Linden</surname><given-names>FA</given-names></name>
<name><surname>Kragt</surname><given-names>JJ</given-names></name>
<name><surname>Hobart</surname><given-names>JC</given-names></name>
<name><surname>Klein</surname><given-names>M</given-names></name>
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
<name><surname>van der Ploeg</surname><given-names>HM</given-names></name>
<etal/>
</person-group>. <article-title>The size of the treatment effect: do patients and proxies agree?</article-title> <source>BMC Neurol</source> <year>2009</year>; <volume>9</volume>: <fpage>12</fpage>.</citation>
</ref>
<ref id="bibr8-1352458511417827">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hobart</surname><given-names>J</given-names></name>
<name><surname>Lamping</surname><given-names>D</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>R</given-names></name>
<name><surname>Riazi</surname><given-names>A</given-names></name>
<name><surname>Thompson</surname><given-names>A</given-names></name>
</person-group>. <article-title>The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure</article-title>. <source>Brain</source> <year>2001</year>; <volume>124</volume>: <fpage>962</fpage>–<lpage>973</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511417827">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hobart</surname><given-names>JC</given-names></name>
<name><surname>Riazi</surname><given-names>A</given-names></name>
<name><surname>Lamping</surname><given-names>DL</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>R</given-names></name>
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)</article-title>. <source>Neurology</source> <year>2003</year>; <volume>60</volume>: <fpage>31</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511417827">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharrack</surname><given-names>B</given-names></name>
<name><surname>Hughes</surname><given-names>RA</given-names></name>
</person-group>. <article-title>The Guy’s Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis</article-title>. <source>Mult Scler</source> <year>1999</year>; <volume>5</volume>: <fpage>223</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511417827">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>RH</given-names></name>
<name><surname>Munschauer</surname><given-names>F</given-names></name>
<name><surname>Linn</surname><given-names>R</given-names></name>
<name><surname>Miller</surname><given-names>C</given-names></name>
<name><surname>Murphy</surname><given-names>E</given-names></name>
<name><surname>Foley</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire</article-title>. <source>Mult Scler</source> <year>2003</year>; <volume>9</volume>: <fpage>95</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511417827">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)</article-title>. <source>Neurology</source> <year>1983</year>; <volume>33</volume>: <fpage>1444</fpage>–<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511417827">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hobart</surname><given-names>JC</given-names></name>
<name><surname>Riazi</surname><given-names>A</given-names></name>
<name><surname>Lamping</surname><given-names>DL</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>R</given-names></name>
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome</article-title>. <source>Health Technol Assess</source> <year>2004</year>; <volume>8</volume>: <fpage>iii</fpage>, <fpage>1-iii</fpage>, <fpage>48</fpage>.</citation>
</ref>
<ref id="bibr14-1352458511417827">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bland</surname><given-names>JM</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
</person-group>. <article-title>Statistical methods for assessing agreement between two methods of clinical measurement</article-title>. <source>Lancet</source> <year>1986</year>; <volume>1</volume>: <fpage>307</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511417827">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McGraw</surname><given-names>KO</given-names></name>
<name><surname>Wong</surname><given-names>SP</given-names></name>
</person-group>. <article-title>Forming inferences about some intraclass correlation coefficients</article-title>. <source>Psychol Methods</source> <year>1996</year>; <volume>1</volume>: <fpage>30</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511417827">
<label>16.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Nunally</surname><given-names>JC</given-names></name>
</person-group>. <source>Psychometric theory</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>, <year>1978</year>.</citation>
</ref>
<ref id="bibr17-1352458511417827">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>J</given-names></name>
</person-group>. <article-title>Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit</article-title>. <source>Psychol Bull</source> <year>1968</year>; <volume>70</volume>: <fpage>213</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr18-1352458511417827">
<label>18.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Fleiss</surname><given-names>JL</given-names></name>
</person-group>. <source>Statistical Methods for Rates and Proportions</source>, <edition>second edition</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>1981</year>.</citation>
</ref>
</ref-list>
</back>
</article>